• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MedAvail Holdings Inc. (Amendment)

    2/14/24 1:51:16 PM ET
    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $MDVL alert in real time by email
    SC 13G/A 1 alyeska-mdvl123123a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    MEDAVAIL HOLDINGS, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    58406B103

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  58406B103
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Investment Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    87,618
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    87,618
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    87,618
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.43%*
    12
    TYPE OF REPORTING PERSON
     
    IA

     The reporting persons are the beneficial owners of 87,618 shares of Common Stock of the Issuer, which constitute approximately 5.43% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 1,613,911 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 14, 2023.

     


     

    CUSIP No.  58406B103
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Fund GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    87,618
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    87,618
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    87,618
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.43%*
    12
    TYPE OF REPORTING PERSON
     
    OO

     The reporting persons are the beneficial owners of 87,618 shares of Common Stock of the Issuer, which constitute approximately 5.43% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 1,613,911 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 14, 2023.

     


     

    CUSIP No.  58406B103
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Anand Parekh
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    87,618
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    87,618
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    87,618
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.43%*
    12
    TYPE OF REPORTING PERSON
     
    IN
    The reporting persons are the beneficial owners of 87,618 shares of Common Stock of the Issuer, which constitute approximately 5.43% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 1,613,911 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 14, 2023.
     


     

     

    CUSIP No. 58406B103
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    MEDAVAIL HOLDINGS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    4720 East Cotton Gin Loop, Suite 220

    Phoenix, Arizona 85040

    Item 2.(a) Names of Person Filing:

    (i) Alyeska Investment Group, L.P.

     

    (ii) Alyeska Fund GP, LLC

     

    (iii) Anand Parekh

      

    Item 2.(b) Address of Principal Business Office:

    (i) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (ii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (iii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

      

    Item 2.(c) Citizenship:

    (i) Alyeska Investment Group, L.P. - Delaware

     

    (ii) Alyeska Fund GP, LLC - Delaware

     

    (iii) Anand Parekh - United States of America

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.001 per share

     

    Item 2.(e) CUSIP No.:

    58406B103

     

    CUSIP No.  58406B103
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 58406B103
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached hereto

    (c) Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto

     The reporting persons are the beneficial owners of 87,618 shares of Common Stock of the Issuer as of December 31, 2023. The percentage calculation assumes that there are currently 1,613,911 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 14, 2023.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 58406B103
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

    By:  Entity and Description

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           

     

     
    CUSIP No. 58406B103
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           
    Get the next $MDVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDVL
    Leadership Updates

    Live Leadership Updates

    See more
    • MedAvail Strengthens Leadership Team

      MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail") a technology-enabled pharmacy company, today announced the appointment of industry leaders Steven Hess to Executive Vice President, General Manager, of SpotRx and Bob McClune to Senior Vice President of Data and Analytics. "We are pleased to have Steven join our senior leadership team. Steven's extensive pharmacy experience across retail and specialty will be integral in leading our strategies to drive profitable growth and optimize our SpotRx hub pharmacy and MedCenter enabled clinic operations. We also welcome Bob to MedAvail to lead our efforts in optimizing and accelerating data exchanges with our clinic partners," said Mark Doerr, Chi

      2/22/22 8:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Announces Changes to Executive Management and Board of Directors; Preliminary Fourth Quarter and FY 2021 Results

      MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), a technology-enabled pharmacy company, today announced that Mark Doerr, RPh, has joined the company as chief executive officer ("CEO") and director, effective January 10, 2022. Mr. Doerr succeeds Ed Kilroy, who retired as CEO and from the board of directors and is moving into an advisory role through March 31, 2022. The company also announced changes to its board of directors and reported preliminary fourth quarter and full year 2021 revenue results. Gerard van Hamel Platerink has stepped down as chairperson of the board of directors. Mr. van Hamel Platerink has served on MedAvail's board of directors since June 2012. He is succeeded by c

      1/11/22 4:15:00 PM ET
      $MDVL
      $ME
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MedAvail Appoints Ramona Seabaugh as Chief Financial Officer

      MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail" or the "Company"), a technology-enabled pharmacy company, today announced the appointment of Ramona Seabaugh as Chief Financial Officer effective immediately. As a key member of MedAvail's executive leadership team, Ms. Seabaugh will lead the Company's financial operations. "Ramona's pharmacy industry expertise and extensive financial leadership experience will be invaluable in executing our strategy to drive operational and financial performance," said Ed Kilroy, President and Chief Executive Officer of MedAvail. "I am pleased to welcome Ramona to our team, as we continue to expand into new geographies and transform the pharmacy experience

      9/20/21 8:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MDVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by MedAvail Holdings Inc. (Amendment)

      SC 13G/A - MedAvail Holdings, Inc. (0001402479) (Subject)

      2/14/24 1:51:16 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13D/A filed by MedAvail Holdings Inc. (Amendment)

      SC 13D/A - MedAvail Holdings, Inc. (0001402479) (Subject)

      2/6/24 5:15:40 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13D/A filed by MedAvail Holdings Inc. (Amendment)

      SC 13D/A - MedAvail Holdings, Inc. (0001402479) (Subject)

      6/21/23 5:15:32 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Faulkner Robert C.

      4 - MedAvail Holdings, Inc. (0001402479) (Issuer)

      2/6/24 9:30:45 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Seabaugh Ramona converted options into 680 shares and sold $1,726 worth of shares (303 units at $5.70), increasing direct ownership by 45% to 1,222 units (SEC Form 4)

      4 - MedAvail Holdings, Inc. (0001402479) (Issuer)

      10/2/23 5:00:26 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Doerr Mark Edward

      4 - MedAvail Holdings, Inc. (0001402479) (Issuer)

      8/21/23 4:47:52 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    SEC Filings

    See more
    • MedAvail Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - MedAvail Holdings, Inc. (0001402479) (Filer)

      2/8/24 4:06:06 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Changes in Registrant's Certifying Accountant, Leadership Update, Financial Statements and Exhibits

      8-K - MedAvail Holdings, Inc. (0001402479) (Filer)

      2/2/24 9:25:12 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Holdings Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - MedAvail Holdings, Inc. (0001402479) (Filer)

      1/23/24 4:38:20 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MedAvail Announces Agreement with New Orleans-Based St. Thomas Community Health Centers for Deployment of Two M4 MedCenters

      PHOENIX, Nov. 28, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, announced today that it has entered into an agreement with New Orleans-based St. Thomas Community Health Centers for the deployment of two M4 MedCenter kiosks. St. Thomas operates eight Federally Qualified Health Centers (FQHCs), providing affordable health care to underserved communities across the New Orleans metropolitan area. "We are very excited to announce this new agreement with St. Thomas, building upon our existing infrastructure in the New Orleans area and growing our presence in the FQHC partner channel, where we see significant long-term gro

      11/28/23 7:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

      PHOENIX, Nov. 17, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail" or the "Company"), an innovative pharmacy technology company, announced today that on November 16, 2023, the Company received a delinquency notification letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to have timely filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission. The delinquency notification letter provides that, under Nasdaq rules, the Company now has 60 calendar days to submit

      11/17/23 4:05:00 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Announces Agreement with ASP Cares for Deployment of Ten M4 MedCenters

      Initial three deployments to be completed in early 2024 at ASP Cares Pharmacy in Las Vegas Agreement repsents expansion of successful relationship with Dallas-based Oak Lawn Pharmacy PHOENIX, Nov. 17, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, announced today that it has entered into an agreement with Pharmacy Fund 1 for the deployment of ten M4 MedCenter kiosks, which will be serviced by ASP Cares Pharmacy. Pharmacy Fund 1 also operates Oaklawn Pharmacy, which is a current MedAvail partner in Dallas, Texas. Per the terms of the agreement, the first three MedCenters are planned to be deployed at First Person

      11/17/23 8:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Financials

    Live finance-specific insights

    See more
    • MedAvail Reports Second Quarter 2023 Financial Results

      PHOENIX, Aug. 14, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today reported financial results for the second quarter ended June 30, 2023. "During the second quarter, we were able to sustain the positive momentum that we have experienced since we began focusing on the immense market opportunity for our pharmacy technology in January of this year," said Mark Doerr, Chief Executive Officer of MedAvail. "Of note, we placed an additional two revenue generating MedCenters in the field, bringing our year-to-date total to six, and we reiterate our expectation that we will place 25 net new revenue generating MedCenters in

      8/14/23 4:49:00 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Reports First Quarter 2023 Financial Results

      PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today reported financial results for the first quarter ended March 31, 2023. "During the first quarter, we made good progress toward our mission of becoming a leader in the development and manufacture of pharmacy technology solutions in the short time since we announced the sale of certain of our SpotRx assets to CVS in January," said Mark Doerr, Chief Executive Officer of MedAvail. "Our pipeline continues to grow, representing a mix of both new and existing partners, and we remain on track to achieve our previously stated goal of adding 25 net new dispe

      5/18/23 4:01:00 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail to Report First Quarter 2023 Financial Results on May 18

      PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets. MedAvail management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Call and webcast details:Thursday, May 18th, 2023 @ 4:30pm ETInvestor dial-in: 1- 877-704-4453 (domestic) or 1-201-389-0920 (international)Conference ID: 13738987To access the Call me™ feature, which avoids having to wait for an operator, click here. The live a

      5/18/23 7:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples